A large, real-world study presented at the AACE Annual Meeting found that adults with osteoporosis prescribed denosumab (Prolia) have no increased long-term risk of atypical femur fractures (AFF) compared to those using bisphosphonates.
Early transition from medium-dose inhaled corticosteroids to biologic therapy in asthma is associated with significantly greater reductions in exacerbations and systemic corticosteroid use compared with escalation to high-dose ICS, suggesting a potential shift in treatment strategy for patients with severe disease or type 2 inflammation.
Excerpt:
The FDA has granted approval to Novartis for Itvisma (onasemnogene abeparvovec-brve), the first gene replacement therapy for spinal muscular atrophy (SMA) available for patients aged 2 years and older. Backed by data from the Phase 3 STEER and Phase 3b STRENGTH trials, this one-time intrathecal treatment addresses the genetic root cause of SMA and is expected to be available in the U.S. this December.
GLP-1 drugs may raise rare optic risks but also protect against severe diabetic eye damage.
